Erschienen in:
24.05.2022 | Editorial
The promise of hypericin: a tracer for acute myocardial infarction
verfasst von:
Mani Salarian
Erschienen in:
Journal of Nuclear Cardiology
|
Ausgabe 6/2022
Einloggen, um Zugang zu erhalten
Excerpt
Myocardial infarction (MI) and subsequent heart failure (HF) is a leading cause of morbidity and mortality worldwide.
1‐3 Acute myocardial infarction (AMI) is usually caused by a thrombus blocking an artery or a bypass graft, characterized by sudden decrease in blood flow to the myocardium, leading to heart failure and death.
4,5 The irreversible injury in MI originates from severe and sustained myocardial ischemia and typically occurs as a result of rupture or erosion of an epicardial coronary artery plaque, which initiates superimposed thrombosis and occlusion of the coronary artery. Alternatively, in the presence of coronary atherosclerosis, myocardial infarction can occur when unfavorable hemodynamics redistribute blood flow away from a myocardial region supplied by a stenotic coronary artery.
6 …